Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| NCI-2015-01757 | Registry Identifier | NCI Clinical Trials Reporting Program (CTRP) |
Not provided
Not provided
Not provided
Low Accrual
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Comprehensive Cancer Network | NETWORK |
Not provided
Not provided
Not provided
Not provided
This phase II trial studies the safety of giving enzalutamide with leuprolide acetate before and after radiation therapy and to see how well it works in treating patients with prostate cancer that is at high risk of returning. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Most types of prostate cancer also need testosterone to grow and spread. After radiation therapy, patients often receive treatments to reduce testosterone to prevent the cancer from returning. Leuprolide acetate works by reducing the amount of testosterone that the body makes. Enzalutamide is a stronger treatment that may block testosterone from reaching cancer cells. Adding enzalutamide to treatment with leuprolide acetate after radiation therapy may help prevent high-risk prostate cancer from returning and improve patient survival.
PRIMARY OBJECTIVES:
I. To determine the feasibility and safety of the combination of enzalutamide and leuprolide acetate (leuprolide) in patients undergoing definitive radiation therapy for high-risk prostate cancer or with pelvic nodal involvement.
II. To determine the prostate-specific antigen (PSA) complete response rate with the combination of enzalutamide and leuprolide (PSA-complete response (CR) as determined by PSA nadir =< 0.3) in patients undergoing radiation therapy for high-risk prostate cancer or pelvic nodal involvement.
SECONDARY OBJECTIVES:
I. To determine time to biochemical failure as determined by the American Society for Radiation Oncology (ASTRO) Phoenix definition of nadir + 2 ng/mL, local progression, regional progression, and distant metastases.
II. To determine time to clinical progression free survival III. To assess changes in PSA nadir and PSA and testosterone levels. IV. To assess changes in hemoglobin A1c (HbA1c), fasting glucose, fasting insulin and fasting lipid and cholesterol levels.
V. To document changes in quality of life outcomes.
EXPLORATORY OBJECTIVES:
I. To identify potential mutations and changes gene copy number associated with enzalutamide resistance in patients with high risk prostate cancer.
II. To identify gene expression patterns, splice variants, and gene signatures associated with enzalutamide treatment and enzalutamide resistance in patients with high risk prostate cancer.
III. To identify changes in the immune response with enzalutamide treatment.
OUTLINE:
Patients receive enzalutamide orally (PO) once daily (QD) and leuprolide acetate intramuscularly (IM) every 1, 3, 4, or 6 months for 24 months. Patients also undergo standard of care intensity-modulated radiation therapy (IMRT) 5 days per week for 5 weeks beginning at week 8, followed by optional brachytherapy. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 6 weeks, 3-4 months, 6, 12, 18, 24, and 36 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Combination Therapy: Enzalutamide, Leuprolide, Radiotherapy | Experimental | Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months. Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enzalutamide | Drug | Given orally |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants With Acute Treatment-related Toxicity | Percentage of participants with acute, treatment-related toxicity defined as <=90 days within the completion of radiotherapy, for any treatment-related grade 3 or higher adverse events as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | From start of treatment to 90 days after completion of radiotherapy, approximately 6 months total |
| Percentage of Participants With Late Treatment-related Toxicity | Percentage of participants with late, treatment-related, toxicity is defined as any toxicity occurring >= 90 days from completion of radiotherapy for any grade 3 or higher treatment-related adverse events as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. | From 90 days after completion of radiotherapy until end of study, approximately 30 months total |
| Proportion of Patients Achieving a Prostate Specific Antigen-Complete Response (PSA-CR) | A PSA measurement will be obtained at 120-127 days after initiation of androgen deprivation therapy. The proportion of patients achieving a PSA-CR (PSA nadir <=0.3) at 120-127 days will be determined. | Up to 127 days |
| Measure | Description | Time Frame |
|---|---|---|
| Median Time to Biochemical Failure | Prostate-specific antigen (PSA) nadir >=2 ng/mL, also known as the Phoenix definition, is the definition most commonly used to establish biochemical failure (BF) after external beam radiotherapy for prostate cancer management. Time to biochemical failure is defined as the time from start of treatment to the time of change in PSA >=2 ng/mL from the nadir. | Up to 36 months |
Not provided
Inclusion Criteria:
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 180 days prior to registration at very high risk of recurrence as determined by 2 or more of the following combinations:
Standard staging exams for patients with high-risk prostate cancer including bone scan or NaF Positron Emission Tomography (PET) /CT scan, and pelvic and prostate MRI.
No distant metastases (M0) on bone scan or NaF PET/CT within 90 days prior to registration. Equivocal bone scan findings are allowed if the physician determines that distant metastases are unlikely based on clinical judgment.
Zubrod Performance Status 0-2 within 60 days prior to enrollment.
Age ≥18
Complete blood count (CBC) with differential obtained within 30 days prior to registration on study, with adequate bone marrow function defined as follows:
Patients, even if surgically sterilized (i.e., status post vasectomy), who:
Patient must be able to provide study-specific informed consent prior to study entry.
Exclusion Criteria:
Definite evidence of metastatic disease
Prior radical prostatectomy or bilateral orchiectomy for any reason
Prior invasive malignancy (except non-melanoma skin cancer) unless disease-free or not requiring systemic therapy for a minimum of 3 years.
Prior systemic chemotherapy for prostate cancer (Note that prior chemotherapy for a different cancer is allowed).
Prior radiotherapy, including brachytherapy, to the region of the prostate that would result in overlap of radiation therapy fields.
Previous hormonal therapy such as LHRH agonists (e.g. goserelin, leuprolide), anti-androgens (e.g. flutamide, bicalutamide), estrogens (e.g. DES), or surgical castration (orchiectomy)
Known hypersensitivity to enzalutamide or related compounds
History of adrenal insufficiency
Patients who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.
Prior allergic reaction to the drugs involved in this protocol.
Cushing's syndrome
Severe chronic renal disease (serum creatinine >2.0 mg/dl and confirmed by creatinine clearance <40 mL/minute)
Chronic liver disease (bilirubin >1.5x ULN, ALT or AST >2x ULN)
Active/Uncontrolled Viral Hepatitis
Chronic treatment with glucocorticoids within one year.
History of seizure including febrile seizure or any condition that may predispose to seizure (e.g., prior stroke, brain arteriovenous malformation, head trauma with loss of consciousness requiring hospitalization). Also, current or prior treatment with antiepileptic medications for the treatment of seizures or history of loss of consciousness or transient ischemic attack within 12 months prior to randomization.
Clinically significant cardiovascular disease including:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Hao Nguyen, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94158 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Combination Therapy: Enzalutamide and Leuprolide | Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months. Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Combination Therapy: Enzalutamide and Leuprolide | Participants will receive Enzalutamide: 160 mg per day, to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months as well as a single Leuprolide 7.5mg injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months. Radiation therapy should begin approximately 8 weeks (+/- 1 week) after the date of the first LHRH agonist/antagonist injection of hormone therapy is given and continue for a total of 5 weeks. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Percentage of Participants With Acute Treatment-related Toxicity | Percentage of participants with acute, treatment-related toxicity defined as <=90 days within the completion of radiotherapy, for any treatment-related grade 3 or higher adverse events as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 | Posted | Number | percentage of participants | From start of treatment to 90 days after completion of radiotherapy, approximately 6 months total |
|
Up to 3 years
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Combination Therapy: Enzalutamide and Leuprolide | Enzalutamide: 160 mg (for 40 mg capsules) per day; Oral administration to begin within 0-7 days of the date of the first Luteinizing Hormone-Releasing Hormone (LHRH) agonist administration for total duration of 24 months. Leuprolide: any duration formulation: single 7.5mg intramuscular injection every month; single 22.5 mg injection every 3 months; single 30mg injection every 4 months; single 45 mg injection every 6-months based on the manufacturer for a total of 24 months; |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Seizure | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Urinary frequency | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
The study closed earlier than expected which resulted in a low accrual
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Hao Nguyen | University of California, San Francisco | (415) 514-5541 | Hao.Nguyen@ucsf.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Sep 5, 2017 | May 28, 2021 | Prot_SAP_000.pdf |
| ICF | No | No | Yes | Informed Consent Form | Oct 23, 2018 | May 28, 2021 | ICF_001.pdf |
Not provided
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
Not provided
Not provided
| ID | Term |
|---|---|
| C540278 | enzalutamide |
| D016729 | Leuprolide |
| D050397 | Radiotherapy, Intensity-Modulated |
| D011878 | Radiotherapy |
| ID | Term |
|---|---|
| D007987 | Gonadotropin-Releasing Hormone |
| D010906 | Pituitary Hormone-Releasing Hormones |
| D007028 | Hypothalamic Hormones |
| D036361 | Peptide Hormones |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Leuprolide | Drug | Given via intramuscular injection |
|
|
| Intensity-Modulated Radiation Therapy | Radiation | A total dose of 45 Gy in 25 fractions of 1.8 Gy each. |
|
|
| Median Time to Local Failure | Local failure was defined as the time from the start of treatment to a biopsy confirmed disease recurrence. | Up to 36 months |
| Number of Participants With Regional or Distant Metastases Over Time | The number of participants with confirmed regional or distant metastases at 24 and 36 months will be reported. | Up to 36 months |
| Median Time to Clinical Progression | Defined as the time from the start of study treatment to confirmed regional or distant metastases | Up to 36 months |
| Overall Median Change in Hemoglobin A1c (HbA1c) Levels During Treatment | HbA1C test results are reported as a percentage. The higher the percentage, the higher your blood sugar levels over the past two to three months. Changes in HbA1c results will be assessed during treatment and the overall median change in HbA1c will be reported. | Up to 24 months |
| Overall Median Change in Fasting Glucose Levels During Treatment | Changes in fasting glucose levels results will be assessed during treatment and the overall median change in fasting glucose levels will be reported. | Up to 24 months |
| Overall Median Change in Fasting Insulin Levels During Treatment | Changes in fasting insulin levels will be assessed during treatment and the overall median change in fasting insulin levels will be reported. | Up to 24 months |
| Overall Median Change in Lipid Levels During Treatment | Changes in fasting lipid levels will be assessed during treatment and the overall median change in fasting lipid levels will be reported. | Up to 24 months |
| Overall Median Change in Total Cholesterol Levels During Treatment | Changes in total cholesterol levels will be assessed during treatment and the overall median change in total cholesterol levels will be reported. | Up to 24 months |
| Overall Median Change in High-Density Lipoprotein (HDL) Cholesterol Levels During Treatment | Changes in fasting HDL levels will be assessed during treatment and the overall median change in fasting HDL will be reported. | Up to 24 months |
| Overall Median Change in Low-Density Lipoprotein (LDL) Cholesterol Levels During Treatment | Changes in fasting LDL levels will be assessed during treatment and the overall median change in fasting LDL will be reported. | Up to 24 months |
| Overall Median Change in Score on the Expanded Prostate Cancer Index Composite (EPIC) During Treatment | The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment and assesses the disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual and Hormonal). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Changes in EPIC scores will be assessed during treatment and the overall median change in scores will be reported. | Up to 24 months |
| Overall Median Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue Scores During Treatment | A PROMIS score of 50 is the average (or mean) score for a specific, relevant group of people under investigation. That group is the reference population. The PROMIS measures the responses use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A score of 40 is one SD lower than the mean of the reference population and a score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue). Changes in the PROMIS fatigue scores will be assessed during treatment and the overall median change in scores will be reported. | Up to 24 months |
| Overall Median Change in EuroQol Group Five Dimensional Questionnaire (EQ-5D) During Treatment | EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. Lower scores indicate less issues/problems with that particular health dimension. Changes in the EQ-5D scores will be assessed during treatment and the overall median change in scores will be reported. | Up to 24 months |
| Overall Median Change in EuroQol Group Visual Analog Scale (EQ-VAS) During Treatment | The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale, similar to a ruler, where the endpoints are labelled with 100='The best health you can imagine' on one end and 0='The worst health you can imagine' on the other, with 50 being the midpoint and participants mark an X on the scale to indicate how their health is on the day of the visit. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. Changes in the EQ-VAS scores will be assessed during treatment and the overall median change in scores will be reported. | Up to 24 months |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status | The ECOG Scale of Performance Status describes a patient's level of functioning in terms of their ability to care for themselves, their daily activity, and physical ability (walking, working, etc.). The scale/grade ranges from 0 to 5 with lower scores indicating a greater level of functioning. | Number | participants |
|
|
|
| Primary | Percentage of Participants With Late Treatment-related Toxicity | Percentage of participants with late, treatment-related, toxicity is defined as any toxicity occurring >= 90 days from completion of radiotherapy for any grade 3 or higher treatment-related adverse events as classified by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. | Posted | Number | percentage of participants | From 90 days after completion of radiotherapy until end of study, approximately 30 months total |
|
|
|
| Primary | Proportion of Patients Achieving a Prostate Specific Antigen-Complete Response (PSA-CR) | A PSA measurement will be obtained at 120-127 days after initiation of androgen deprivation therapy. The proportion of patients achieving a PSA-CR (PSA nadir <=0.3) at 120-127 days will be determined. | Posted | Number | proportion of participants | Up to 127 days |
|
|
|
| Secondary | Median Time to Biochemical Failure | Prostate-specific antigen (PSA) nadir >=2 ng/mL, also known as the Phoenix definition, is the definition most commonly used to establish biochemical failure (BF) after external beam radiotherapy for prostate cancer management. Time to biochemical failure is defined as the time from start of treatment to the time of change in PSA >=2 ng/mL from the nadir. | Only participants experiencing biochemical failure are reported | Posted | Median | 95% Confidence Interval | months | Up to 36 months |
|
|
|
| Secondary | Median Time to Local Failure | Local failure was defined as the time from the start of treatment to a biopsy confirmed disease recurrence. | Posted | Median | 95% Confidence Interval | months | Up to 36 months |
|
|
|
| Secondary | Number of Participants With Regional or Distant Metastases Over Time | The number of participants with confirmed regional or distant metastases at 24 and 36 months will be reported. | Posted | Count of Participants | Participants | Up to 36 months |
|
|
|
| Secondary | Median Time to Clinical Progression | Defined as the time from the start of study treatment to confirmed regional or distant metastases | Posted | Median | 95% Confidence Interval | months | Up to 36 months |
|
|
|
| Secondary | Overall Median Change in Hemoglobin A1c (HbA1c) Levels During Treatment | HbA1C test results are reported as a percentage. The higher the percentage, the higher your blood sugar levels over the past two to three months. Changes in HbA1c results will be assessed during treatment and the overall median change in HbA1c will be reported. | Posted | Median | Full Range | percentage | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Fasting Glucose Levels During Treatment | Changes in fasting glucose levels results will be assessed during treatment and the overall median change in fasting glucose levels will be reported. | Posted | Median | Full Range | mg/dL | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Fasting Insulin Levels During Treatment | Changes in fasting insulin levels will be assessed during treatment and the overall median change in fasting insulin levels will be reported. | Data for fasting insulin was not collected | Posted | Up to 24 months |
|
|
| Secondary | Overall Median Change in Lipid Levels During Treatment | Changes in fasting lipid levels will be assessed during treatment and the overall median change in fasting lipid levels will be reported. | Posted | Median | Full Range | mg/dL | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Total Cholesterol Levels During Treatment | Changes in total cholesterol levels will be assessed during treatment and the overall median change in total cholesterol levels will be reported. | Posted | Median | Full Range | mg/dL | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in High-Density Lipoprotein (HDL) Cholesterol Levels During Treatment | Changes in fasting HDL levels will be assessed during treatment and the overall median change in fasting HDL will be reported. | Posted | Median | Full Range | mg/dL | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Low-Density Lipoprotein (LDL) Cholesterol Levels During Treatment | Changes in fasting LDL levels will be assessed during treatment and the overall median change in fasting LDL will be reported. | Posted | Median | Full Range | mg/dL | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Score on the Expanded Prostate Cancer Index Composite (EPIC) During Treatment | The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment and assesses the disease-specific aspects of prostate cancer and its therapies and comprises four summary domains (Urinary, Bowel, Sexual and Hormonal). Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing better health related quality of life. Changes in EPIC scores will be assessed during treatment and the overall median change in scores will be reported. | Two participants did not complete the questionnaire | Posted | Median | Full Range | score on a scale | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue Scores During Treatment | A PROMIS score of 50 is the average (or mean) score for a specific, relevant group of people under investigation. That group is the reference population. The PROMIS measures the responses use a T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A score of 40 is one SD lower than the mean of the reference population and a score of 60 is one SD higher than the mean of the reference population. For PROMIS measures, higher scores equals more of the concept being measured (e.g., more Fatigue). Changes in the PROMIS fatigue scores will be assessed during treatment and the overall median change in scores will be reported. | Two participants did not complete the questionnaire | Posted | Median | Full Range | score on a scale | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in EuroQol Group Five Dimensional Questionnaire (EQ-5D) During Treatment | EQ-5D is a standardized instrument for measuring generic health status. The health status is measured in terms of five dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The respondents self-rate their level of severity for each dimension by selecting one of the following responses: no problems (0), slight problems (1), mild problems (2), moderate problems (3), or severe problems (4) with a particular dimension. Lower scores indicate less issues/problems with that particular health dimension. Changes in the EQ-5D scores will be assessed during treatment and the overall median change in scores will be reported. | Two participants did not complete the questionnaire | Posted | Median | Full Range | score on a scale | Up to 24 months |
|
|
|
| Secondary | Overall Median Change in EuroQol Group Visual Analog Scale (EQ-VAS) During Treatment | The EQ-VAS records the patient's self-rated health on a vertical visual analogue scale, similar to a ruler, where the endpoints are labelled with 100='The best health you can imagine' on one end and 0='The worst health you can imagine' on the other, with 50 being the midpoint and participants mark an X on the scale to indicate how their health is on the day of the visit. The VAS can be used as a quantitative measure of health outcome that reflect the patient's own judgement. Changes in the EQ-VAS scores will be assessed during treatment and the overall median change in scores will be reported. | Two participants did not complete the questionnaire | Posted | Median | Full Range | score on a scale | Up to 24 months |
|
|
|
| 0 |
| 11 |
| 1 |
| 11 |
| 11 |
| 11 |
| Urinary urgency | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary retention | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary incontinence | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Cystitis noninfective | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Chronic kidney disease | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Renal and urinary disorders - Other | Renal and urinary disorders | CTCAE (4.0) | Systematic Assessment |
|
| Hot flashes | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| Lymphedema | Vascular disorders | CTCAE (4.0) | Systematic Assessment |
|
| Erectile dysfunction | Reproductive system and breast disorders | CTCAE (4.0) | Systematic Assessment |
|
| Reproductive system and breast disorders - Other | Reproductive system and breast disorders | CTCAE (4.0) | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Gastroesophageal reflux disease | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Proctitis | Gastrointestinal disorders | CTCAE (4.0) | Systematic Assessment |
|
| Weight gain | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Aspartate aminotransferase increased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Creatinine increased | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Weight loss | Investigations | CTCAE (4.0) | Systematic Assessment |
|
| Cognitive disturbance | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Dysgeusia | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | CTCAE (4.0) | Systematic Assessment |
|
| Fatigue | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| General disorders and administration site conditions - Other | General disorders | CTCAE (4.0) | Systematic Assessment |
|
| Musculoskeletal and connective tissue disorder - Other | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Skin and subcutaneous tissue disorders - Other | Skin and subcutaneous tissue disorders | CTCAE (4.0) | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | CTCAE (4.0) | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | CTCAE (4.0) | Systematic Assessment |
|
| Libido decreased | Psychiatric disorders | CTCAE (4.0) | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D005832 |
| Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D006728 | Hormones |
| D006730 | Hormones, Hormone Substitutes, and Hormone Antagonists |
| D009479 | Neuropeptides |
| D010455 | Peptides |
| D000602 | Amino Acids, Peptides, and Proteins |
| D009842 | Oligopeptides |
| D009419 | Nerve Tissue Proteins |
| D011506 | Proteins |
| D020266 | Radiotherapy, Conformal |
| D011881 | Radiotherapy, Computer-Assisted |
| D013812 | Therapeutics |
| Title | Measurements |
|---|---|
|
| Sexual |
|
| Hormonal |
|
| Title | Measurements |
|---|---|
|
| Pain/Discomfort |
|
| Anxiety/Depression |
|